PLURPLURI INC.
Is Pluri struggling financially?
Yes, by its own account. Pluri told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
15/100
Critical
- Sector
- Biotech/Pharma
- Market cap
- $18.5M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 31 Mar 2026
Cash runway
1–2 mo
Runs out some time after May 2026, raising nothing.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$3.4M
÷
Cash burned over the last 12 months
$38.4M
What Pluri told the SEC
…for a period of less than three months from the issuance date of these interim unaudited condensed consolidated financial statements. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The interim unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets or liabilities that might…
PLURI INC., Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 61.0% share-count increase The company issued stock. Each share now owns 37.9% less of the business than a year ago, before any change in the price.
- Cash burn is increasing It is spending 22% more cash per year than it was, so the runway above shortens even if nothing else changes.
Other Biotech/Pharma companies that filed the doubt
- GCTK Glucotrack $3.7M
- VNRX Volitionrx $5.7M
- TNON Tenon Medical $4.6M
- CRIS Curis $3.3M
- NTHI Neonc Technologies Holdings $121.3M
- NXL Nexalin Technology $7.3M